(Q51746524)
Statements
The JUPITER trial results boost the evidence for the use of hsCRP as a treatment target and as part of the assessment of vascular risk: time for new guidelines? (English)
Dimitri P Mikhailidis
1 reference
Vasilios G Athyros
Konstantinos Tziomalos
Asterios Karagiannis
Dimitri P Mikhailidis